oxidopamine and hu 308
oxidopamine has been researched along with hu 308 in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| de Lago, E; Fernández-Ruiz, J; García-Arencibia, M; González, S; Mechoulam, R; Ramos, JA | 1 |
| Fernández-Ruiz, J; García, C; García-Arencibia, M; Palomo-Garo, C; Pertwee, R; Ramos, J | 1 |
Other Studies
2 other study(ies) available for oxidopamine and hu 308
| Article | Year |
|---|---|
Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties.
Topics: Animals; Antioxidants; Arachidonic Acids; Benzoxazines; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Cannabinoids; Disease Models, Animal; Dopamine; Furans; Male; Morpholines; Naphthalenes; Nerve Degeneration; Neuroprotective Agents; Organ Culture Techniques; Oxidative Stress; Oxidopamine; Parkinsonian Disorders; Polyunsaturated Alkamides; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Superoxide Dismutase; Sympatholytics | 2007 |
Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease.
Topics: Animals; Antioxidants; Cannabinoids; Cyclohexanols; Disease Models, Animal; Dopamine; Dronabinol; Glutamic Acid; Lipopolysaccharides; Male; Mice; Motor Activity; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Substantia Nigra; Tyrosine 3-Monooxygenase | 2011 |